{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+C&page=3", "query": { "intervention": "Dose C", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 3876, "total_pages": 388, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+C&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+C&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T07:33:21.090Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07624513", "title": "D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Isatuximab", "type": "DRUG" }, { "name": "Iberdomide", "type": "DRUG" }, { "name": "Bortezomib (B)", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Linvoseltamab", "type": "DRUG" }, { "name": "On Body Delivery System (OBDS)", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 720, "start_date": "2026-08-31", "completion_date": "2038-03-01", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-10-19T07:33:21.090Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07624513" }, { "nct_id": "NCT06038578", "title": "A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Adenocarcinoma", "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "TRK-950", "type": "BIOLOGICAL" }, { "name": "Ramucirumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Toray Industries, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 146, "start_date": "2023-10-04", "completion_date": "2027-10-31", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-19T07:33:21.090Z", "location_count": 14, "location_summary": "Duarte, California • Irvine, California • Santa Monica, California + 6 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Arlington", "state": "Texas" }, { "city": "Bedford", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06038578" }, { "nct_id": "NCT00819390", "title": "Chloroquine for Reducing Immune Activation in HIV- Infected Individuals", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Chloroquine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2009-03", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2014-10-13", "last_synced_at": "2026-10-19T07:33:21.090Z", "location_count": 15, "location_summary": "Birmingham, Alabama • San Diego, California • Aurora, Colorado + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00819390" }, { "nct_id": "NCT04509596", "title": "DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer Metastatic" ], "interventions": [ { "name": "DZD1516 mono therapy in Part A, DZD1516 in combination with trastuzumab and/or capecitabine in Part B, DZD1516 in combination with T-DM1 in Part C", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dizal Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2020-09-21", "completion_date": "2022-07-07", "has_results": false, "last_update_posted_date": "2025-04-01", "last_synced_at": "2026-10-19T07:33:21.090Z", "location_count": 1, "location_summary": "Santa Monica, California", "locations": [ { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04509596" }, { "nct_id": "NCT06208150", "title": "A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Talquetamab", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Teclistamab", "type": "DRUG" }, { "name": "Elotuzumab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 838, "start_date": "2024-01-22", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-19T07:33:21.090Z", "location_count": 49, "location_summary": "Clovis, California • Santa Monica, California • New Haven, Connecticut + 41 more", "locations": [ { "city": "Clovis", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Newark", "state": "Delaware" }, { "city": "Hollywood", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06208150" }, { "nct_id": "NCT02706626", "title": "Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "brigatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Criterium, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2017-03-09", "completion_date": "2021-04-01", "has_results": true, "last_update_posted_date": "2023-01-26", "last_synced_at": "2026-10-19T07:33:21.090Z", "location_count": 4, "location_summary": "Denver, Colorado • Durham, North Carolina • Nashville, Tennessee + 1 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02706626" }, { "nct_id": "NCT01887418", "title": "Pharmacokinetic Study of Testosterone Enanthate", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hypogonadism" ], "interventions": [ { "name": "QuickShot™ - 50 mg Treatment B", "type": "DRUG" }, { "name": "QuickShot™ - 100 mg Treatment A", "type": "DRUG" }, { "name": "Delatestryl 200 mg IM Treatment C", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Antares Pharma Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "MALE", "summary": "18 Years to 75 Years · Male only" }, "enrollment_count": 39, "start_date": "2013-09", "completion_date": "2014-01", "has_results": true, "last_update_posted_date": "2018-01-11", "last_synced_at": "2026-10-19T07:33:21.090Z", "location_count": 1, "location_summary": "Brookline, Massachusetts", "locations": [ { "city": "Brookline", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01887418" }, { "nct_id": "NCT02247349", "title": "BMS-986012 in Relapsed/Refractory SCLC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Small Cell Lung Cancer" ], "interventions": [ { "name": "BMS-986012 (anti-fucosyl-GM1)", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 106, "start_date": "2014-11-14", "completion_date": "2022-12-22", "has_results": true, "last_update_posted_date": "2024-03-05", "last_synced_at": "2026-10-19T07:33:21.090Z", "location_count": 3, "location_summary": "New York, New York • Durham, North Carolina • Winston-Salem, North Carolina", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02247349" }, { "nct_id": "NCT03203915", "title": "Metabolic Response to Chardonnay Grape Marc Powder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Dyslipidemia", "Obesity" ], "interventions": [ { "name": "Chardonnay grape marc marc high polyphenol dose (120mg)", "type": "DIETARY_SUPPLEMENT" }, { "name": "Chardonnay grape marc powder low polyphenol dose (75mg)", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo (0mg)", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "USDA, Western Human Nutrition Research Center", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "35 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "35 Years to 65 Years" }, "enrollment_count": 31, "start_date": "2017-08-01", "completion_date": "2019-06-28", "has_results": false, "last_update_posted_date": "2021-07-16", "last_synced_at": "2026-10-19T07:33:21.090Z", "location_count": 1, "location_summary": "Davis, California", "locations": [ { "city": "Davis", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03203915" }, { "nct_id": "NCT03821935", "title": "Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors Cancer" ], "interventions": [ { "name": "Livmoniplimab", "type": "DRUG" }, { "name": "Budigalimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 364, "start_date": "2019-02-21", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2025-05-25", "last_synced_at": "2026-10-19T07:33:21.090Z", "location_count": 21, "location_summary": "Springdale, Arkansas • Duarte, California • Irvine, California + 16 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Celebration", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03821935" } ] }